Catalyst Wire Dossier Catalyst Wire Dossier
CLINICAL_TRIALS trial_result · 2023-06-29

Clinical Trial Update: A Phase 3 Study of Tenapanor to Treat Hyperphosphatemia in ESRD Patients on Dialysis [Phase 3]

View source ↗

Summary

Phase 3 trial update for tenapanor in hyperphosphatemia among end-stage renal disease patients on dialysis; results posted after completion.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

Drugs mentioned

  • Tenapanor (tenapanor)

Snippet

Sponsor: Ardelyx | Conditions: Hyperphosphatemia | Phase 3 | Status: COMPLETED | Results posted: 2023-06-29